DK2675826T3 - Antistof mod CSF-1R - Google Patents

Antistof mod CSF-1R Download PDF

Info

Publication number
DK2675826T3
DK2675826T3 DK12707246.0T DK12707246T DK2675826T3 DK 2675826 T3 DK2675826 T3 DK 2675826T3 DK 12707246 T DK12707246 T DK 12707246T DK 2675826 T3 DK2675826 T3 DK 2675826T3
Authority
DK
Denmark
Prior art keywords
ser
csf
antibody
leu
val
Prior art date
Application number
DK12707246.0T
Other languages
English (en)
Inventor
Hélène Haegel
Christine Thioudellet
Michel Geist
Jean-Baptiste Marchand
Benoît Grellier
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of DK2675826T3 publication Critical patent/DK2675826T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Claims (18)

1. Isoleret rekombinant eller oprenset antistof, som specifikt binder til CSF-1R, mere foretrukkent humant CSF-1R, kendetegnet ved, at antistoffet omfatter: (i) (a) en første variabel region bestående af SEQ ID NO:42, og (b) en anden variabel region bestående af SEQ ID NO:44; eller (ii) (a) en første variabel region bestående af SEQ ID NO:43, og (b) en anden variabel region besstående af SEQ ID NO:45; eller (iii) (a) en første variabel region bestående af SEQ ID NO:42, og (b) en anden variabel region bestående af SEQ ID NO:46.
2. Antistof ifølge krav 1 (i), hvor det omfatter (a) en tung kæde bestående af SEQ ID NO:37, og (b) en let kæde bestående af SEQ ID NO:39.
3. Antistof ifølge krav 1 (ii), hvor det omfatter (a) en tung kæde bestående af SEQ ID NO :38, og (b) en let kæde bestående af SEQ ID NO:40.
4. Antistof ifølge krav 1 (iii), hvor det omfatter (a) en tung kæde bestående af SEQ ID NO:37, og (b) en let kæde bestående af SEQ ID NO:41.
5. Antistof ifølge krav 1, som er et polyklonalt antistof, et monoklonalt antistof, en Fab, en Fab', en F(ab')2, en Fv, en scFv, et antigenbindende fragment eller et dialegeme.
6. Nukleinsyresekvens, som koder for et antistof ifølge ethvert af kravene 1 til 5.
7. Vektor indeholdende nukleinsyresekvensen ifølge krav 6.
8. Vektor ifølge krav 7, som er af plasmid eller viral oprindelse.
9. Vektor ifølge krav 8, som er af viral oprindelse og som er afledt af en koppevirus, en adenovirus, en retrovirus, en herpesvirus, en alphavirus, en foamyvirus eller en adeno-associeret virus.
10. Vektor ifølge krav 9, hvor koppevirussen er en vacciniavirus eller en canariekoppevirus.
11. Vektor ifølge krav 10, hvor vacciniavirussen er en MVA.
12. Celle omfattende nukleinsyresekvensen ifølge krav 6.
13. Celle ifølge krav 12, som er en eukaryotisk celle.
14. Celle ifølge krav 13, hvor den eukaryotiske celle er en mammal celle, fortrinsvis en CHO eller en BHK celle.
15. Fremgangsmåde til fremstilling af et antistof ifølge ethvert af kravene 1 til 5, omfattende dyrkning af en celle ifølge ethvert af kravene 12 til 14 under betingelser, som tillader ekspression af antistoffet, og oprensning af antistoffet fra cellen eller mediet, som omgiver cellen.
16. Farmaceutisk sammensætning omfattende antistoffet ifølge ethvert af kravene 1 til 5, nukleinsyresekvensen ifølge krav 6 eller vektoren ifølge ethvert af kravene 7 til 11 og et farmaceutisk acceptabelt bærestof.
17. Antistof ifølge ethvert af kravene 1 til 5, nukleinsyresekvensen ifølge krav 6, vektoren ifølge ethvert af kravene 7 til 11 eller den farmaceutiske sammensætning ifølge krav 16 til anvendelse som et lægemiddel.
18. Antistof ifølge ethvert af kravene 1 til 5, nukleinsyresekvensen ifølge krav 6, vektoren ifølge ethvert af kravene 7 til 11 eller den farmaceutiske sammensætning ifølge krav 16, til anvendelse ved behandlingen af en sygdom valgt fra gruppen bestående af cancer, en sygdom associeret med en forøget osteoclastaktivitet, inflammatorisk sygdom og rheumatoid arthritis.
DK12707246.0T 2011-02-14 2012-02-07 Antistof mod CSF-1R DK2675826T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/026,944 US8470977B2 (en) 2008-03-14 2011-02-14 Antibody against the CSF-1R
PCT/EP2012/052043 WO2012110360A1 (en) 2011-02-14 2012-02-07 Antibody against the csf-1r

Publications (1)

Publication Number Publication Date
DK2675826T3 true DK2675826T3 (da) 2018-01-22

Family

ID=45808764

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12707246.0T DK2675826T3 (da) 2011-02-14 2012-02-07 Antistof mod CSF-1R

Country Status (18)

Country Link
US (3) US8470977B2 (da)
EP (1) EP2675826B1 (da)
JP (1) JP5996558B2 (da)
KR (1) KR101920946B1 (da)
CN (2) CN104140467B (da)
AU (1) AU2012217303B2 (da)
BR (1) BR112013020500A8 (da)
CA (1) CA2825243A1 (da)
DK (1) DK2675826T3 (da)
ES (1) ES2654551T3 (da)
HK (1) HK1203976A1 (da)
HU (1) HUE035617T2 (da)
IL (1) IL227078A (da)
MX (1) MX347020B (da)
RU (1) RU2621859C2 (da)
SG (1) SG191899A1 (da)
WO (1) WO2012110360A1 (da)
ZA (1) ZA201306869B (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
WO2009112245A1 (en) 2008-03-14 2009-09-17 Transgene S.A. Antibody against the csf-1 r
SI2510010T1 (sl) 2009-12-10 2016-02-29 F. Hoffmann-La Roche Ag Protitelesa, vezavna na ekstracelično domeno 4 humanega csf1r in njihova uporaba
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
JP2013521765A (ja) 2010-03-05 2013-06-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
NZ626610A (en) 2010-05-04 2015-11-27 Five Prime Therapeutics Inc Antibodies that bind csf1r
DK2734547T3 (da) 2011-07-18 2017-04-03 Univ Melbourne Anvendelse af c-fms-antistoffer
CA2851771C (en) * 2011-10-21 2018-09-11 Transgene Sa Modulation of macrophage activation
EA201700111A1 (ru) 2011-10-28 2018-02-28 Тева Фармасьютикал Австралия Пти Лтд Полипептидные конструкции и их применение
CN104159921B (zh) 2011-12-15 2018-05-04 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
SG10201906328RA (en) 2012-08-31 2019-08-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AU2013343556B2 (en) 2012-11-09 2018-06-28 Transgene Sa Modulation of monocytes, or precursors thereof, differentiation
AU2014253090B2 (en) 2013-04-12 2018-10-25 Morphosys Ag Antibodies targeting M-CSF
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB201315486D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
KR20230086809A (ko) 2014-06-23 2023-06-15 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법
JP6895374B2 (ja) 2014-07-16 2021-06-30 トランジェーヌＴｒａｎｓｇｅｎｅ 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス
US10765710B2 (en) 2014-07-16 2020-09-08 Institut Gustave-Roussy Combination of oncolytic virus with immune checkpoint modulators
SI3212670T1 (sl) 2014-10-29 2021-03-31 Five Prime Therapeutics, Inc. Kombinirana terapija proti raku
AU2015369854B2 (en) 2014-12-22 2021-07-01 Five Prime Therapeutics, Inc. Anti-CSF1R antibodies for treating PVNS
TWI725966B (zh) 2015-04-13 2021-05-01 戊瑞治療有限公司 癌症組合療法
KR102451786B1 (ko) * 2015-04-28 2022-10-05 미쓰비시 타나베 파마 코퍼레이션 RGMa 결합 단백질 및 그 사용
CN113940996A (zh) * 2015-05-27 2022-01-18 Ucb生物制药私人有限公司 用于治疗神经系统疾病的方法
EP3349794A4 (en) * 2015-09-16 2019-07-31 Ablexis, LLC ANTI-CD115 ANTIBODIES
CA3024985A1 (en) 2016-06-16 2017-12-21 Farmhannong Co., Ltd. Methods and compositions for conferring and/or enhancing herbicide tolerance using protoporphyrinogen oxidase or variant thereof
IL263834B2 (en) 2016-06-20 2024-01-01 Kymab Ltd Antibodies against PD-L1
AU2016413999B2 (en) 2016-07-05 2020-05-14 Ibentrus, Inc. Cancer treatment composition for inhibiting tumor angiogenesis, containing VEGF deep blocker, and preparation method therefor
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
US20180194838A1 (en) * 2017-01-10 2018-07-12 National Yang-Ming University Method for treating cancer metastasis and composition thereof
BR112020004879A2 (pt) 2017-09-13 2020-09-15 Five Prime Therapeutics, Inc. métodos para tratar o câncer pancreático, para tratar o câncer e para determinar a responsividade de um sujeito com câncer
CN109096397B (zh) * 2018-07-18 2019-04-16 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及应用
TWI733274B (zh) * 2018-12-13 2021-07-11 財團法人生物技術開發中心 抗人類csf-1r抗體及其用途
TW202112812A (zh) 2019-05-24 2021-04-01 香港商安立璽榮生醫(香港)有限公司 Csf1r抗體、il10融合蛋白及其用途
JP2022550069A (ja) 2019-09-26 2022-11-30 エフ．ホフマン－ラ ロシュ アーゲー 抗ｃｓｆ－１ｒ抗体
RU2751249C1 (ru) * 2020-10-28 2021-07-12 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с csf-1r
CN114907489A (zh) * 2022-04-24 2022-08-16 首都医科大学附属北京天坛医院 一种可诱导嵌合抗原受体及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US317403A (en) * 1885-05-05 Seal-lock for car-doors
US59113A (en) * 1866-10-23 Improvement in horse-rakes
US245471A (en) * 1881-08-09 fabwell
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH0517367A (ja) 1991-07-08 1993-01-26 Green Cross Corp:The 骨粗鬆症治療剤
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5747323A (en) 1992-12-31 1998-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retroviral vectors comprising a VL30-derived psi region
DK0689447T3 (da) 1993-02-16 1999-10-18 Onyx Pharma Inc Cytopatiske vira til behandling af og profylakse for neoplasia
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6107045A (en) * 1994-06-30 2000-08-22 Oklahoma Medical Research Foundation Antibodies to lipoproteins and apolipoproteins and methods of use thereof
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
DE50002293D1 (de) 1999-10-28 2003-06-26 Hofbauer Reinhold Verwendung von csf-1-inhibitoren
CA2473570A1 (fr) 2002-01-03 2003-07-24 Transgene S.A. Antisens diriges contre le csf-1 humain
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
JP5422101B2 (ja) 2004-01-07 2014-02-19 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
US7534604B2 (en) 2004-01-16 2009-05-19 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
AU2007284651B2 (en) * 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
RS56743B1 (sr) 2007-08-21 2018-03-30 Amgen Inc Humani c-fms antigen vezujući proteini
WO2009112245A1 (en) * 2008-03-14 2009-09-17 Transgene S.A. Antibody against the csf-1 r
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
CA2851771C (en) * 2011-10-21 2018-09-11 Transgene Sa Modulation of macrophage activation
AU2013343556B2 (en) * 2012-11-09 2018-06-28 Transgene Sa Modulation of monocytes, or precursors thereof, differentiation

Also Published As

Publication number Publication date
AU2012217303B2 (en) 2016-10-20
ZA201306869B (en) 2014-05-28
US20170002081A1 (en) 2017-01-05
KR101920946B1 (ko) 2018-11-21
US9982055B2 (en) 2018-05-29
JP5996558B2 (ja) 2016-09-21
NZ612038A (en) 2014-09-26
RU2621859C2 (ru) 2017-06-07
SG191899A1 (en) 2013-08-30
KR20140032992A (ko) 2014-03-17
CA2825243A1 (en) 2012-08-23
CN104140467B (zh) 2017-05-31
CN104140467A (zh) 2014-11-12
MX2013009362A (es) 2014-04-25
ES2654551T3 (es) 2018-02-14
BR112013020500A8 (pt) 2018-01-09
US20110178278A1 (en) 2011-07-21
IL227078A (en) 2017-06-29
WO2012110360A1 (en) 2012-08-23
AU2012217303A1 (en) 2013-07-11
BR112013020500A2 (pt) 2016-10-18
US8470977B2 (en) 2013-06-25
MX347020B (es) 2017-04-06
CN103476794A (zh) 2013-12-25
US9428584B2 (en) 2016-08-30
RU2013141956A (ru) 2015-03-27
JP2014506572A (ja) 2014-03-17
CN103476794B (zh) 2017-05-03
EP2675826B1 (en) 2017-11-01
EP2675826A1 (en) 2013-12-25
HUE035617T2 (en) 2018-05-28
US20130289250A1 (en) 2013-10-31
HK1203976A1 (en) 2015-11-06

Similar Documents

Publication Publication Date Title
US9982055B2 (en) Antibody against the CSF-1R
EP2262836B1 (en) Antibody against the csf-1 r
NZ612038B2 (en) Antibody against the csf-1r